Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369915 · ClinicalTrials.gov registry record · Phase 2
The Antidepressant Efficacy of the Anticholinergic Scopolamine
A Phase 2 study, sponsored by National Institute of Mental Health (NIMH).
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00369915 is a Phase 2 study that was terminated before completion, run by National Institute of Mental Health (NIMH). The registered enrollment target is 17 participants.
The verdict
NCT00369915, a Phase 2 study, was terminated before completion, sponsored by National Institute of Mental Health (NIMH).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
A previous study showed that the intravenous administration of scopolamine produces antidepressant effects. This study is designed to determine if other routes of administration of scopolamine produce antidepressant effects.
Interventions
- DRUG Scopolamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2006-08 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369915
The ClinicalTrials.gov registry entry for NCT00369915 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Scopolamine is the first listed.
NCT00369915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00369915 about?
NCT00369915 is a clinical study titled "The Antidepressant Efficacy of the Anticholinergic Scopolamine". A previous study showed that the intravenous administration of scopolamine produces antidepressant effects. This study is designed to determine if other routes of administration of scopolamine produce antidepressant effects.
What is the current status of trial NCT00369915?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2006-08. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00369915?
The interventions under investigation include: Scopolamine (DRUG).
Who is sponsoring clinical trial NCT00369915?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.